131i-rituximab
mAbexperimentalADC
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2011 (NCT01678404)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD20Radiodepletion
MS4A1 radiodepletion
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 131-iodine
Oral
No
Parenteral
No
Topical
No
Also known as
- 131i-rituximab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01676558 | Phase 2 | Jun 1, 2012 | Korea Cancer Center Hospital |
| NCT01678417 | Phase 2 | Jun 1, 2012 | Korea Cancer Center Hospital, Korea University |
| NCT01678404 | Phase 2 | Oct 1, 2011 | Korea Cancer Center Hospital, Korea University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Korea Cancer Center Hospital | Academic/Hospital | 3 | 3 | 1 | 2011 |
| Korea University | Academic/Hospital | 2 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1